Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

According to our mission, we serve people with all of our skills, so that they can live a long and healthy life. That is why we chose to support the comprehensive nationwide screening program as a Golden Sponsor in 2019. The state-of-the-art screening truck will tour around the country until Christmas, stopping by 200 spots to offer screenings in 37 different areas.

Health means more than just the lack of illnesses.